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Under replication stress, cells deficient in
the fork remodeler HLTF fail to slow DNA
replication. Here, Bai et al. report that,
when HLTF is disrupted, replication is
completed by alternative PRIMPOL- or
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DNA replication stress can stall replication forks, leading to genome instability. DNA damage tolerance path-
ways assist fork progression, promoting replication fork reversal, translesion DNA synthesis (TLS), and rep-
riming. In the absence of the fork remodeler HLTF, forks fail to slow following replication stress, but under-
lyingmechanisms and cellular consequences remain elusive. Here, we demonstrate that HLTF-deficient cells
fail to undergo fork reversal in vivo and rely on the primase-polymerase PRIMPOL for repriming, unrestrained
replication, and S phase progression upon limiting nucleotide levels. By contrast, in an HLTF-HIRANmutant,
unrestrained replication relies on the TLS protein REV1. Importantly, HLTF-deficient cells also exhibit
reduced double-strand break (DSB) formation and increased survival upon replication stress. Our findings
suggest that HLTF promotes fork remodeling, preventing other mechanisms of replication stress tolerance
in cancer cells. This remarkable plasticity of the replication fork may determine the outcome of replication
stress in terms of genome integrity, tumorigenesis, and response to chemotherapy.
INTRODUCTION
A variety of DNA-damaging agents, protein-DNA complexes,
and DNA secondary structures can threaten genome stability
by slowing replication fork progression, a condition defined as
replication stress (Zeman and Cimprich, 2014). Nucleotide
depletion induced by oncogene activation or hydroxyurea (HU)
treatment also causes replication stress (Kotsantis et al.,
2018). Cells initiate a complex response to replication fork stall-
ing that allows them to maintain fork stability and, ultimately,
complete DNA replication (Cortez, 2019). This response is tightly
regulated and coordinated by the checkpoint kinase ATR, which
is activated by single-stranded DNA (ssDNA)-containing DNA
structures that form when replication forks stall (Saldivar et al.,
2017). Unresolved or persistent stalled forks are vulnerable
structures susceptible to nucleolytic processing and double-
strand break (DSB) formation and, ultimately, cause genome
instability (Cortez, 2019; Pasero and Vindigni, 2017).
DNA-damage tolerance (DDT) pathways are another crucial
response to replication stress (Branzei and Szakal, 2017). Repli-
cation fork reversal is one form of DDT proposed to protect fork
integrity during replication stress (Neelsen and Lopes, 2015). By
reannealing the nascent DNA strands on each sister chromatid
to form a fourth regressed arm, fork reversal actively converts
the three-armed fork into a Holliday junction (HJ)-like structure.
Different kinds of genotoxic stress can lead to helicase-polymer-
ase uncoupling and ssDNA accumulation, but fork reversal re-
strains replication fork progression and is thought to prevent
ssDNA accumulation at the fork (Neelsen and Lopes, 2015;
Ray Chaudhuri et al., 2012; Zellweger et al., 2015). Fork reversal
may also promote template switching and error-free lesion
bypass (Cortez, 2019; Neelsen and Lopes, 2015; Saugar et al.,
2014). Thus, it is proposed to protect and resolve stalled replica-
tion forks.
Two other forms of DDT are also possible in mammalian cells.
Specialized translesion synthesis (TLS) polymerases can directly
bypass DNA lesions in order to resume DNA synthesis, prevent-
ing persistent replication fork stalling and, ultimately, DSB for-
mation (Sale, 2013; Saugar et al., 2014). Alternatively, repriming
can restart DNA synthesis downstream of a stalled polymerase.
In higher eukaryotes, a central effector of this process is the pri-
mase-polymerase PRIMPOL, which can utilize its DNA primase
activity to reprimeDNA synthesis downstreamof the lesion, leav-
ing a ssDNA gap behind the fork (Bianchi et al., 2013; Garcia-
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Gómez et al., 2013; Keen et al., 2014; Kobayashi et al., 2016;
Mourón et al., 2013; Pilzecker et al., 2016; Schiavone et al.,
2016; Svikovic et al., 2019; Wan et al., 2013). After PRIMPOL ex-
tends the DNA primer by a few nucleotides using its polymerase
activity, the replicative polymerase can continue nascent DNA
synthesis. Howmammalian cells choose between the alternative
forms of DDT—fork reversal, TLS, and repriming—is not clear,
although several proteins have been implicated in regulating
these processes.
Proliferating cell nuclear antigen (PCNA) is a central regulator
of DDT. In yeast and higher eukaryotes, PCNA monoubiquitina-
tion promotes TLS polymerase recruitment and lesion bypass in
a potentially error-pronemanner (Hoege et al., 2002; Sale, 2013).
PCNA polyubiquitination, mediated by the E3 ligase Rad5 in
yeast, promotes template switching, which uses the sister chro-
matid as a template for error-free lesion bypass (Branzei and
Szakal, 2017; Hoege et al., 2002). In mammalian cells, the E3
ubiquitin ligases HLTF and SHPRH contribute to PCNA poly-
ubiquitination, although polyubiquitination is still observed
upon the loss of both proteins (Saugar et al., 2014; Unk et al.,
2010). This implies that additional factors are likely involved
and that DDT processes are more complex in mammalian cells.
In higher eukaryotes, multiple proteins participate in fork re-
modeling via replication fork reversal, although the distinct con-
tributions of each are not known (Neelsen and Lopes, 2015).
Three regulators of the process—SMARCAL1, ZRANB3, and
HLTF—are members of the SWI/SNF2 family. Each of these re-
modelers is capable of fork reversal in vitro (Achar et al., 2011;
Bansbach et al., 2009; Betous et al., 2012; Blastyák et al.,
2010; Ciccia et al., 2009, 2012; Couch et al., 2013; Yuan et al.,
2012; Yusufzai et al., 2009), and each is recruited to the replica-
tion fork through distinct interactions (Poole and Cortez, 2017).
Electron microscopy (EM) studies also indicate that SMARCAL1
and ZRANB3 are required for fork reversal in vivo (Kolinjivadi
et al., 2017; Vujanovic et al., 2017; Zellweger et al., 2015), but
whether HLTF is needed in vivo has not been addressed.
HLTF, like its yeast ortholog Rad5, contains an ATPase
domain and an E3 ubiquitin ligase domain (Unk et al., 2010).
Both proteins also contain a HIRAN domain, which binds specif-
ically to 30-OH ssDNA ends. HLTF’s ATPase and 30 ssDNA bind-
ing activities are needed for fork reversal in vitro (Achar et al.,
2015; Chavez et al., 2018; Hishiki et al., 2015; Kile et al., 2015).
In vivo, HLTF slows replication fork progression upon nucleotide
depletion, and in its absence, forks fail to slow and progress un-
restrained. As the HIRAN domain is needed to restrain replica-
tion fork progression, fork reversal and fork slowing may be
linked (Kile et al., 2015). Indeed, the loss of two other proteins
involved in fork reversal, RAD51 and ZRANB3, also leads to un-
restrained fork progression upon replication stress (Vujanovic
et al., 2017; Zellweger et al., 2015). How unrestrained replication
fork progression is sustained in the absence of HLTF is unknown.
Increased endogenous replication stress is a hallmark of can-
cer cells and can be induced by nucleotide depletion or condi-
tions that perturb DNA replication, including oncogene activation
and deregulation of origin firing (Kotsantis et al., 2018). Interest-
ingly, HLTF is frequently silenced in colorectal cancer (Moinova
et al., 2002), and its deficiency accelerates tumorigenesis in a
mouse model (Sandhu et al., 2012). This suggests that HLTF is
a tumor suppressor (Dhont et al., 2016). Given HLTF’s ability to
restrain DNA replication and its potential role in cancer, we
sought to understand how HLTF affects the replication stress
response and the role of HLTF-mediated fork remodeling in
this process.
Here, we report that HLTF loss limits DSB formation and pro-
motes increased resistance to replication stress, allowing cells
to continue DNA replication using PRIMPOL. Surprisingly, a spe-
cific defect in HLTF’s HIRAN domain also leads to unrestrained
DNA replication and replication stress resistance, but, in this
case, via REV1-mediated TLS. Our results suggest that HLTF’s
activities are central to regulate replication fork reversal and to
prevent alternative mechanisms of stress-resistant DNA replica-
tion that promote DNA synthesis, S phase progression, and
cellular resistance to replication stress. They also demonstrate
the remarkable plasticity of the replication fork in tolerating repli-
cation stress when fork reversal is disrupted. Therefore, we pro-
pose that HLTF loss may promote tumorigenesis by unleashing
alternative, and potentially more mutagenic, modes of replica-
tion stress tolerance.
RESULTS
HLTF Promotes Fork Reversal and Restrains Fork
Progression In Vivo
HLTF promotes fork reversal in vitro on model replication fork
structures (Achar et al., 2011; Blastyák et al., 2010). To test
whether HTLF can also promote fork reversal in vivo, we used
EM to monitor fork reversal in HLTF-KO (knockout) cell lines
generated using CRISPR targeting (Figure S1A) (Kile et al.,
2015). After exposing control and HLTF-KO cells to a low dose
of HU (50 mM), we isolated replication intermediates and
analyzed their structure using in vivo psoralen crosslinking and
EM. Reversed fork structures represented approximately 23%
of the replication intermediates we observed in HU-treated
wild-type (WT) cells (Figures 1A and 1B), consistent with the
number of reversed forks observed following other types of treat-
ment (Zellweger et al., 2015). By contrast, both HLTF-KO cell
lines exhibited a significant 2- to 3-fold reduction in reversed
fork frequency. This finding demonstrates that HLTF is a bona
fide fork-reversal protein in human cells.
A lack of fork reversal in vivo is associated with unrestrained
fork progression (Vujanovic et al., 2017; Zellweger et al., 2015),
and our previous data suggest that HLTF loss also leads to this
phenotype (Kile et al., 2015). To confirm and extend this finding,
we monitored fork progression using the dose of HU used in the
fork reversal assay and a dose of the DNA crosslinker, mitomycin
C (MMC), which induces fork reversal in vivo (Vujanovic et al.,
2017). Briefly, we pulse-labeled cells with the thymidine ana-
logiododeoxyuridine (IdU), added the drug during a second
chlorodeoxyuridine (CldU) pulse, and examined fork progression
using DNA spreading (Figure 1C). In contrast toWT cells in which
replication tracts were shortened by about 30% upon drug treat-
ment, replication tracts in both HLTF-KO clones were unaffected
and, thus, exhibited unrestrained fork progression (Figure 1D).
We also observed this phenotype in chronic myelogenous leuke-
mia K562 cells and non-cancerous retina pigmented epithelium
RPE1 HLTF-KO cell lines (Figures S1A and S1B; Table S1).
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These findings suggest that HLTF’s ability to restrain fork pro-
gression is not cell type specific and occurs in response to mul-
tiple types of replication stress.
PRIMPOL Is Required for Unrestrained Replication Fork
Progression in HLTF-Deficient Cells
Intrigued by the nature of the unrestrained fork progression, we
next asked whether the replication observed in HLTF-KOs was
continuous or whether forks might use another mode of DNA
synthesis in these cells. In fact, recent studies suggest that the
unrestrained replication observed in HLTF-deficient cells may
be associated with discontinuous DNA replication (Peng et al.,
2018). To test whether replication is discontinuous in our
HLTF-KO cells, we treated cells with 50 mM HU and then incu-
bated permeabilized cells with and without S1 nuclease. This
ssDNA-specific nuclease cleaves replication intermediates that
contain ssDNA formed at gaps or DNA secondary structures















































































































































































Figure 1. HLTF Promotes Fork Reversal
In Vivo and Limits PRIMPOL-Mediated Unre-
strained Fork Progression
(A) Electron micrographs of representative replica-
tion intermediates. Black arrows indicate fork
junctions. Scale bars: 500 nm in main images;
20 nm in insets.
(B) Frequency of reversed replication forks in WT or
HLTF-KO U2OS cells treated with 50 mMHU for 1 h.
Means ± SEM (nR 3). ***p < 0.001; ****p < 0.0001,
by one-way ANOVA and then Dunnett’s test.
(C) Experimental setup for replication fork pro-
gression assay. Representative fields of DNA fibers
are indicated. Scale bar: 15 mm.
(D) Dot plot and median of CldU tract lengths for 3
independent experiments (n = 3). ****p < 0.0001, by
Kruskal-Wallis test; ns, not significant.
(E and F) Dot plot and median of CldU tract lengths
after control or siPRIMPOL-3 knockdown in mock
or HU-treated (50 mM) cells (E) and treated with or
without S1 nuclease (F). Open circles, no treatment;
closed circles, HU treatment (n = 3). *p < 0.05;
****p < 0.0001, by Mann-Whitney test; ns, not sig-
nificant.
See also Figure S1.
ically shortened replication tracts pro-
duced in HLTF-KO cells under HU-
induced replication stress (Figure S1C).
This finding strongly suggests that replica-
tion proceeds in a discontinuous way
when HLTF is lost, with the production of
ssDNA gaps.
In higher eukaryotes, de novo priming
mediated by PRIMPOL facilitates fork pro-
gression by allowing the replisome to skip
over barriers, leaving a ssDNA gap behind
the fork (Garcia-Gómez et al., 2013; Wan
et al., 2013). To determine whether PRIM-
POL mediates discontinuous replication in
HLTF-KO cells under conditions of nucleo-
tide depletion, we knocked down PRIMPOL and monitored fork
progression. Replication tracts were significantly shortened spe-
cifically in HLTF-KO cells treated with HU after PRIMPOL knock-
down, consistent with the idea that PRIMPOL supports replica-
tion under these conditions (Figure 1E; Figure S1D). Similar
results were obtained with a second PRIMPOL small interfering
RNA (siRNA) (Figure S1E). Importantly, S1 nuclease treatment
only marginally affected tract length when PRIMPOL was
knocked down, indicating that replication was no longer discon-
tinuous (Figure 1F). Moreover, PRIMPOL levels were similar in
WT and HLTF-KO cells after HU treatment, suggesting that the
observed effects are unlikely to reflect PRIMPOL upregulation
in the HLTF-KOs (Figure S1F). To confirm PRIMPOL’s role in un-
restrained fork progression, we knocked out PRIMPOL in our
HLTF-KO cells and in WT cells using CRISPR targeting (Fig-
ure S1G; Table S1). Consistent with the results obtained using
the PRIMPOL siRNAs, KO of PRIMPOL in the HLTF-KO cells pre-
vented unrestrained fork progression (Figure S1H). Taken
ll
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together, our results strongly suggest that PRIMPOL promotes
unrestrained fork progression in HLTF-KO cells under conditions
of mild replication stress.
PRIMPOLPromotes SPhaseProgression in theAbsence
of HLTF
As HLTF loss allows unrestrained fork progression upon replica-
tion stress, we next asked how HLTF status affects the cell cycle.
HLTF-KO and WT cells have similar cell-cycle distributions in the
absence of replication stress (Figure S2A). By contrast, upon
treatment with a low dose of HU for 6 h, we observed significant
differences in the cell-cycle profiles, with fewer HLTF-deficient
cells in S phase and more in G2 phase (Figure S2A). As effects
on fork progression are immediately observed in DNA fiber
experiments (Figures 1C and 1D), we reasoned that cell-cycle
differences were due to increased S phase progression in
HLTF-deficient cells, which we measured using a quantitative im-
age-based cytometry (QIBC) assay (Saldivar et al., 2018). Briefly,
asynchronous cells were pulsed with 5-ethynyl-20-deoxyuridine
(EdU), allowed to progress through the cell cycle with or without
HU, then pulsed with bromodeoxyuridine (BrdU) and imaged (Fig-
ure 2A). The lack of BrdU staining in EdU-positive cells (Figure 2B,
red dots) signals successful transition from S to G2 phase.
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Figure 2. HLTF Loss Promotes PRIMPOL-
Dependent S to G2 Cell-Cycle Progression
(A) Experimental setup for S to G2 cell-cycle pro-
gression assay.
(B) QIBC generated scatterplots. 1,500 cells per
sample were randomly selected to generate the
scatterplot.
(C) Fraction of EdU-positive cells that progressed to
G2 phase was determined as described in STAR
Methods. Mean ± SEM (n = 3). ****p < 0.0001, by
two-way ANOVA and then Dunnett’s test. Test re-
sults for HU-treated HLTF-KO versus U2OS cells
are indicated.
(D) S-G2 progression assay, as described in (A) and
(C), in indicated cells. Mean ± SEM (n = 3). **p <
0.01; ****p < 0.0001, by two-way ANOVA and then
Dunnett’s test; ns, not significant. Test results for
HU-treated PRIMPOL-KO or HLTF-PRIMPOL-dKO
versus U2OS cells are indicated.
See also Figure S2.
Both WT and HLTF-KO cell lines simi-
larly progressed through S phase in the
absence of HU (Figure 2C; Figure S2B). In
the presence of HU, WT cells slowed S
phase progression as expected, and very
few cells entered G2. Strikingly, however,
both HLTF-KO clones completed S phase
more quickly (Figures 2B and 2C). The
same results were obtained with RPE1
cells (Figure S2C). These findings suggest
that the faster fork progression observed
in HLTF-KO cells allows them to progress
more rapidly through S phase.
To better understand this mechanism,
we asked whether the accelerated S phase progression
observed in HLTF-KO cells was dependent upon PRIMPOL.
PRIMPOL-KOs and HLTF-PRIMPOL-double KOs (dKOs)
behaved similarly to WT cells in the absence of HU treatment
(Figure S2D), suggesting no significant effect of PRIMPOL loss
on normal S phase progression. PRIMPOL-KOs also slowed S
phase progression like WT cells when treated with HU (Fig-
ure 2D). By contrast, S phase progression was significantly
slowed in the HU-treated HLTF-PRIMPOL-dKO cells relative to
the HLTF-KOs, although the HLTF-PRIMPOL-dKO cells were
still faster than the WT cells (Figure 2D). Similar results were
observed after PRIMPOL knockdown (Figure S2E). Taken
together, our data suggest that unrestrained fork progression,
primarily driven by PRIMPOL, promotes S phase progression
in HLTF-deficient cells.
HLTF Loss Limits DNA-Damage Signaling and DSB
Formation
Proper control of replication fork speed can alleviate replication
stress and suppress the DNA-damage response (Maya-Men-
doza et al., 2018). As HLTF-deficient cells fail to slow fork speed
and S phase progression under conditions of low-dose HU treat-
ment (50 mM), we examined DNA-damage signaling in HLTF-
ll
Article








































1 4 8Time in HU (h)
C



















































0h 2h 4h 6h
0h 2h 4h 6h
B





































































































































































































































 HU treatment time (h)
Figure 3. HLTF Loss Limits DNA-Damage Signaling, RPA Chromatin Binding, and DSB Formation
(A) Western blot of indicated proteins in WT and HLTF-KO U2OS cells treated with 3 mM HU for the time indicated.
(B) Cells were treated with 3mMHU for the indicated time. Total DAPI as well as mean RPA and gH2AX intensities were measured at the single-cell level by QIBC
after pre-extraction. Scatterplot of single cells with RPA intensity (y axis) versus DAPI intensity (x axis) is shown. Mean gH2AX intensity per cell is indicated for
each cell using a color scale. Box indicates the gated RPA-positive population used for analyses shown in (C) and (E). ~1,500 cells were randomly selected for
each sample.
(legend continued on next page)
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KOs using higher HU doses (3mM) to facilitate detection of dam-
age signaling. Surprisingly, we found that HU-induced markers
of DNA-damage signaling, including markers of ATR and ATM
activation, were reduced in the absence of HLTF (Figure 3A).
Replication stress can lead to helicase-polymerase uncou-
pling, activating ATR through the accumulation of replication
protein A (RPA)-coated ssDNA (Saldivar et al., 2017). Prolonged
replication stress induced by nucleotide depletion leads to
excessive ssDNA accumulation, resulting in the depletion of
the RPA available for ssDNA protection (‘‘RPA exhaustion’’). Un-
protected ssDNA leads to DNA breaks and ATM activation, a
condition described as ‘‘replication catastrophe’’ (Couch et al.,
2013; Toledo et al., 2013, 2017). To further investigate the impact
of HLTF loss on DNA-damage signaling, we used QIBC to quan-
titatively monitor RPA chromatin binding and phospho-H2AX
(gH2AX), analyzing RPA and gH2AX levels in the subset of cells
with increased RPA chromatin binding (RPA-positive cells) (Fig-
ures 3B and 3C), as previously reported (Toledo et al., 2013). This
single-cell analysis allowed us to avoid biases that might arise
from cell-cycle differences. HU treatment increased RPA chro-
matin binding in both WT and HLTF-KO S phase cells. Remark-
ably, however, HLTF-KO clones exhibited significantly less RPA
chromatin binding than the WT cells throughout the HU treat-
ment (Figures 3B and 3C). Furthermore, RPA-positive cells ex-
hibited reduced H2AX phosphorylation at the single-cell level
in HLTF-KO clones (Figure 3C). H2AX can be phosphorylated
by ATR, ATM, and DNA-PK in response to multiple types of
DNA damage and replication stress. Therefore, we also moni-
tored RPA phosphorylation on T21 and S4/8. These sites are
phosphorylated by the DSB-activated kinases ATM and/or
DNA-PK, and both sites are phosphorylated during replication
catastrophe (Marechal and Zou, 2015; Toledo et al., 2013). Sur-
prisingly, RPA phosphorylation at both sites was significantly
reduced in the RPA-positive HLTF-KO cells (Figure 3C), strongly
suggesting that DSB formation is reduced. To further test this
idea, we directly monitored DSB formation using the neutral
comet assay. Both HLTF-KO U2OS clones showed reduced
DSB formation (Figure 3D), as did HLTF-deficient K562 cell lines
(Figure S3A). Thus, we conclude that HLTF loss reduces DNA-
damage signaling and DSB formation under conditions of repli-
cation stress.
Upon nucleotide depletion, DSB formation occurs when RPA
is no longer available to protect exposed ssDNA, resulting in
replication catastrophe (Toledo et al., 2013, 2017). Because we
observed less RPA chromatin binding in HLTF-deficient cells,
we asked whether the reduced damage signaling observed
was simply a consequence of reduced RPA chromatin binding
and, therefore, increased availability of free RPA. If true, WT
and HLTF-KO cells would have similar levels of damage
signaling under conditions in which RPA chromatin binding
was the same. By contrast, if HLTF has another role in promoting
DNA damage, HLTF loss would still reduce damage signaling
when RPA chromatin binding is equal.
To distinguish between these possibilities, we repeated the
QIBC experiments in cells pre-treated with an ATR inhibitor
(ATRi) and then exposed to HU. ATR inhibition causes excessive
origin firing, accelerating ssDNA accumulation, RPA chromatin
binding, and DSB formation (Couch et al., 2013; Toledo et al.,
2013). The absence of ATRi during HU treatment allows ATR to
remain active under conditions of replication stress, preventing
disruption of other ATR functions that could lead to DSB forma-
tion. Importantly, under these conditions, HLTF loss dramatically
reduced H2AX phosphorylation even when RPA chromatin bind-
ing was similar (Figure 3E, left). Furthermore, RPA phosphoryla-
tion on T21 and S4/8was reduced (Figure 3E, right). Similar dam-
age signaling effects were observed when ATRi and HU were
combined to increase replication stress (Figure S3B). These find-
ings strongly suggest that HLTF’s absence reduces break for-
mation even when the pool of free RPA is exhausted, thereby un-
coupling RPA exhaustion from DSB formation. They also
indicate that HLTF’s effects on DNA damage are not a direct
result of RPA exhaustion and that HLTF has a separate role in
promoting DSB formation. Taken together, our results demon-
strate that HLTF loss promotes a different replication mode
upon stress, which is associated with reduced DSB formation
and reduced DNA-damage signaling.
HLTF Loss Promotes Resistance to Replication Stress
HLTF-deficient cells exhibit less DNA breaks and less DNA-dam-
age signaling, progressing more rapidly through S phase thanWT
cells. We, therefore, tested the long-term impact of HLTF loss on
cells by performing colony survival assays. Surprisingly, under a
range of HU doses, including those used to assess DNA damage
and signaling, HLTF-KO cells exhibited increased resistance to
HU-induced replication stress (Figure 4A). ATR inhibitors are un-
der investigation for the treatment of cancer (Lecona and Fernan-
dez-Capetillo, 2018). As HLTF loss protects cells from DNA dam-
age induced by ATR inhibition combined with HU treatment
(Figure S3B), we tested the impact of this combination on survival
and found that HLTF-KO cells were more resistant (Figure 4B).
(C) Cells are treated as in (B), and data are presented as a scatterplot with mean RPA intensity (x axis) versus mean gH2AX/pRPA (S4/8 or T21) intensity (y axis).
Individual cells with different RPA, gH2AX and pRPA intensities are colored as follows: RPA-negative cells are indicated in green, and RPA-positive cells are
indicated in red (RPA+, in red boxes), unless they also stain positive for pRPA (pRPA-S4/8+ or pRPA-T21+, indicated in light blue and in light blue boxes). Total
intensities (mean intensity 3 nuclear area) were calculated to account for differences in the nuclear size of isogenic WT and HLTF-KO cell lines. Population
medians of total cellular RPA or gH2AX intensities and percentage of pRPA-S4/8+ or pRPA-T21+ cells among RPA-positive cells from each experiment were
averaged to generate the plot, ± SEM (nR 3). *p < 0.05; **p < 0.01; ***p < 0.001 by one-way ANOVA and then Dunnett’s test; ns, not significant. Test results for
each HLTF-KO clone versus WT are indicated.
(D) Neutral comet assay results of WT and HLTF-KO U2OS cells after 24 h of HU (3 mM) treatment (n = 3). ****p < 0.0001 by one-way ANOVA and then Dun-
nett’s test.
(E) Cells were treated with 5 mMATRi for 80 min and after washout with 3 mM HU for the indicated times. Total RPA, gH2AX intensities, and percentage of pRPA
S4/8+ or T21+ cells among RPA-positive cells are plotted as described in (C) (n R 3). **p < 0.01; ***p < 0.001; ****p < 0.0001, by one-way ANOVA and then
Dunnett’s test; ns, not significant. Test results for each HLTF-KO clone versus WT are indicated.
See also Figure S3.
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Remarkably, increased resistancewas also observed in HLTF-KO
cells treated with MMC (Figure 4C). Collectively, these findings
suggest that HLTF loss protects cells from replication stress and
fork collapse induced by a variety of treatments.
HLTF Loss Protects Cells from Replication Stress in a
PRIMPOL-Independent Manner
PRIMPOL sustains unrestrained replication in HLTF’s absence
while promoting S phase progression, raising the possibility
that HLTF-deficient cells may depend on PRIMPOL for their
replication stress response (Figures 1E and 2D). Therefore, we
asked how PRIMPOL affects the accumulation of DNA breaks,
DNA-damage signaling, and survival in HU-treated WT and
HTLF-KO cells. We found that PRIMPOL-KOs exhibited signifi-
cantly increased RPA chromatin binding and higher gH2AX
and pRPA levels (Figure 5A). Consistent with the increased
DNA-damage signaling, PRIMPOL-KO cells were sensitive to
HU (Figure 5B), as previously reported (Kobayashi et al., 2016).
Furthermore, neutral comet assays indicate elevated DSB for-
mation in PRIMPOL-KO cells treated with HU (Figure 5C). These
observations suggest that PRIMPOL reduces RPA chromatin
binding and DSB formation, likely by reducing ssDNA exposure
through repriming and DNA synthesis or by simply binding to
ssDNA. More importantly, HLTF loss in PRIMPOL-KO cells
(HLTF-PRIMPOL-dKOs) reduced gH2AX and pRPA to WT levels
(Figure 5A), suggesting that HLTF loss limits DSB formation even
when PRIMPOL is absent. Comet assays also suggest that HLTF
loss reduces DSB formation in a PRIMPOL-deficient back-
ground (Figure 5C). Moreover, HLTF-PRIMPOL-dKO cells were
less sensitive to HU than PRIMPOL-KOs in a survival assay (Fig-
ure 5B). Similar results were obtained upon knockdown of PRIM-
POL (Figures S4A and S4B). Taken together, these findings
demonstrate that HLTF loss can protect cells from replication
stress in a process that is independent of PRIMPOL.
The HLTF HIRAN Mutant Promotes an Alternative
Mechanism of Stress-Resistant DNA Replication
HLTF’s ATPase and HIRAN domains are required for replication
fork reversal activity in vitro. Moreover, transient expression of a
HIRAN mutant incapable of fork reversal in vitro failed to restrain
fork progression in HLTF-KOs (Kile et al., 2015). To explore the
HIRAN domain’s impact on the HLTF-dependent functions
described herein, we first expressed and purified the HLTF
R71E mutant protein and tested ATPase, fork regression, and
ubiquitin ligase activities. As expected, this mutant retained its
ATPase activity but had significantly impaired fork reversal activ-
ity (Figures 6A and 6B). In addition, this mutation did not impact
HLTF’s ability to mediate PCNA ubiquitination (Figure 6C). Thus,
the R71E HIRAN mutant has lost its ability to reverse replication
forks, but its ATPase and ubiquitin ligase activities remain intact.
Next, we generated HLTF-KO cells stably expressing WT or
the R71E mutant HLTF. Although designed to be doxycycline
inducible, HLTF was expressed in the absence of induction,
and doxycycline addition only modestly increased protein
expression (Figure S5A). Nevertheless, we carried out all exper-
iments in the presence of doxycycline. WT HLTF was expressed
in all selected clones at levels slightly higher than that of the
endogenous protein, while the R71E mutant was expressed at
levels similar to the endogenous protein.
First, we asked whether the WT-HLTF or R71E mutant could
restrain fork progression upon HU treatment. HU-treated cells
expressing WT-HLTF slowed fork progression, while cells ex-
pressing the R71E mutant did not, consistent with our previous
results (Kile et al., 2015) (Figure S5B). Next, we sought to deter-
mine whether the unrestrained fork progression observed in the
HIRANmutant was discontinuous, as observed in HLTF-KOs, by





























































Figure 4. HLTF Loss Promotes Resistance to Replication Stress
(A–C) Clonogenic survival assay of WT and HLTF-KO U2OS cells after treat-
ment with HU (A), 3 mM HU and 5 mM ATRi (B), or MMC (C). Mean ± SEM (n =
3). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 by one-way ANOVA and
then Dunnett’s test; ns, not significant. Test results for each HLTF-KO clone
versus WT are indicated.
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nuclease treatment did not shorten replication tracts produced in
R71E-HLTF cells, while it did so in the HLTF-KO cells (Figure 6D).
By contrast, HLTF-KO cells expressing the WT-HLTF protein
slowed fork progression and were insensitive to S1 treatment,
as observed in control U2OS cells (Figure 6D). These findings
suggest that the unrestrained replication observed in cells ex-
pressing the HIRAN mutant is mechanistically distinct from that
observed in the HLTF-KO cells. To further characterize this
phenotype, we tested the impact of knocking down PRIMPOL
in these cells. Consistent with the lack of S1 sensitivity, PRIM-
POL knockdown in cells expressing the R71E mutant had no ef-
fect on replication fork progression (Figure 6E). These findings
demonstrate that the HIRAN mutant cells are still capable of un-
restrained fork progression and that this fork progression occurs
in a PRIMPOL-independent manner.
To further investigate the role of the HIRAN domain in the
cellular replication stress response, we monitored S phase pro-
gression in these cells. In the absence of HU, cells expressing
either the WT or R71E mutant HLTF protein progress through S
phase at a rate similar to that of WT or HLTF-KOU2OS cells (Fig-
ure S5C). Intriguingly, however, upon HU treatment, HLTF-KO
cells expressing R71E-HLTF progressed through S phase
more rapidly than HLTF-KO cells expressingWT-HLTF or normal
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Figure 5. HLTF Loss Protects Cells from
Replication Stress in a PRIMPOL-Indepen-
dent Manner
(A) Total RPA and gH2AX intensities and percent-
age of pRPA-T21+ and pRPA S4/8+ cells were
measured in RPA-positive cells, as in Figure 3C. For
PRIMPOL-KOs or PRIMPOL-HLTF dKOs, 3 clones
of each genotype were analyzed individually and
averaged for each independent experiment in (A) to
(C). Mean ± SEM (n = 4). *p < 0.05; **p < 0.01; ***p <
0.001; ****p < 0.0001 by one-way ANOVA and then
Dunnett’s test; ns, not significant. Test results for
PRIMPOL-KO or HLTF-PRIMPOL-dKO versus WT
are indicated.
(B) Clonogenic survival assay in indicated cells after
24 h of HU (3 mM) treatment. Mean ± SEM (n = 2).
PRIMPOL-KO or PRIMPOL-HLTF-dKO results are
compared to those of WT cells in a statistical test.
*p < 0.05; **p < 0.01, by two tailed t test; ns, not
significant.
(C) Neutral comet assay in indicated cells after 24 h
of HU (3 mM) treatment. Mean ± SEM (n = 2). ****p <
0.0001, by two-tailed Mann-Whitney test.
See also Figure S4.
U2OS cells yet more slowly than HLTF-KO
cells (Figure 6F). Thus, the unrestrained
fork progression observed in the HIRAN
mutant sustains faster S phase progres-
sion, although to a lesser extent than that
resulting from HLTF loss.
Finally, we addressed the impact of the
HIRAN domain on cell survival and DNA-
damage signaling. HLTF-KO cells ex-
pressing either WT-HLTF or the R71E
mutant exhibited levels of H2AX and RPA
phosphorylation (T21 and S4/8) similar to those observed in con-
trol U2OS cells (Figure S5D). As expected, expression of WT-
HLTF fully restored cellular sensitivity to HU in the HLTF-KOs.
Surprisingly, however, expression of the R71E-HLTF mutant
did not significantly change the HU sensitivity of HLTF-KOs (Fig-
ure 6G). Taken together, these findings suggest that HLTF loss
and expression of a mutant HLTF incapable of fork reversal
enable different mechanisms of unrestrained fork progression,
both leading to increased cellular resistance to replication stress.
REV1 Is Required for Unrestrained Replication Fork
Progression in the HIRAN Mutant
Next, we asked how cells expressing the R71E mutant sustain
replication fork progression independent of PRIMPOL. The yeast
ortholog of HLTF, Rad5, interacts with REV1, a BRCT-domain-
containing Y family polymerase that facilitates the recruitment
of TLS polymerases to stressed replication forks to continue
DNA synthesis (Gallo et al., 2019; Kuang et al., 2013; Pages
et al., 2008; Xu et al., 2016). Because PRIMPOL is not required
for unrestrained DNA replication in the R71E mutant, we hypoth-
esized that TLS might sustain fork progression in this scenario.
To test this idea, we knocked down REV1 in the HLTF-KO cells
expressing either WT HLTF or the R71E mutant (Figure S6A).
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Figure 6. The HLTF HIRAN Mutant Promotes an Alternative Mechanism of Stress-Resistant DNA Replication
(A) Left: representative TLC plates. Right: quantification of DNA-dependent ATPase activity of indicated protein. Mean ± SEM (n = 3).
(B) Left: representative native PAGE results showing fork regression experiment. Model DNA forks were incubated with WT or HIRAN mutant HLTF proteins.
Asterisks represent the position of the 50-32P-labeled oligonucleotide in the fork structure and product. Right: quantification of the results shown on the left.
Mean ± SEM (n = 3).
(C) Western blot (a-PCNA) analysis of HLTF-dependent PCNA polyubiquitylation using either WT or R71E mutant HLTF.
(D) Dot plot andmedian CldU tract length in indicated cells with or without S1 nuclease treatment after mock or HU (50 mM) treatment during CldU labeling (n = 3).
****p < 0.0001, by two-tailed Mann-Whitney test; ns, not significant.
(E) Dot plot andmedian CldU tract length in indicated cells after control or siPRIMPOL-3 knockdown. Cells were labeled and HU treated as described in (D) (n = 3).
****p < 0.0001, by two-tailed Mann-Whitney test; ns, not significant.
(F) S-G2 progression, as described in Figure 2.Mean ± SEM (n = 3). **p < 0.01; ****p < 0.0001, by two-way ANOVA and then Dunnett’s test; ns, not significant. Test
results for WT or R71E-rescue versus U2OS are indicated.
(G) Colony formation following 24 h of HU treatment. Mean ± SEM (n = 3). *p < 0.05; **p < 0.01, by one-way ANOVA and thenDunnett’s test; ns, not significant. Test
results for WT or R71E-rescue versus U2OS are indicated.
See also Figure S5.
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Although REV1 knockdown had no effect on fork progression in
either theHLTF-KO cells or KO cells expressing theWTprotein, it
prevented unrestrained fork progression in the R71E mutant cell
lines (Figure 7A).
To further validate this result, we monitored replication fork
progression in R71E cells treated with a REV1 inhibitor that
directly binds to REV1’s C-terminal domain and disrupts its abil-
ity to recruit TLS polymerases (Sail et al., 2017). Treatment with
this inhibitor had minimal effect on fork progression in the HLTF-
KO or WT HLTF cells (Figure 7B). However, the inhibitor signifi-
cantly slowed replication fork progression in the R71E mutant,
consistent with REV1 knockdown. Taken together, these results
demonstrate that cells expressing the R71E-HLTF mutant, but
not WT-HLTF or HLTF-KO cells, rely on REV1 for replication
fork progression under conditions of replication stress.
DISCUSSION
Here, we show that HLTF mediates a complex replication stress
response, promoting replication fork reversal and, as a result,
suppressing alternative, stress-resistant mechanisms of DNA
replication. When HLTF is lost, as occurs by silencing in some
cancers, cells become resistant to replication stress (Figure 7C).
We identify at least two HLTF functions that may contribute to
replication stress sensitivity. First, HLTF restrains replication
fork and S phase progression by promoting fork reversal and
suppressing alternative mechanisms of DNA synthesis. Second,
HLTF exposes cells to DSB formation upon prolonged replica-
tion stress. We hypothesize that, unless promptly restarted,
reversed forks or other Holliday junction-like structures gener-
ated by HLTF are targeted by structure-specific nucleases to
produceDSBs.We also suggest that HLTF regulates the balance
between fork reversal, repriming, and TLS and that human cells
initially attempt fork reversal under stress conditions, likely to
minimize mutation. In the absence of, or as an alternative to,
fork reversal, replication forks demonstrate remarkable plasticity
in their ability to continue DNA synthesis, through either discon-
tinuous PRIMPOL-dependent replication or continuous REV1-
dependent replication.
HLTF Promotes Fork Reversal In Vivo and Suppresses
Multiple Mechanisms of Stress-Resistant Replication
Fork Progression
Here, we provide direct evidence that HLTF is a bona fide fork-
reversal protein in vivo, using EM, the gold standard in this field




















































































































































































Figure 7. REV1 Is Required for Unrestrained
Replication Fork Progression in the HIRAN
Mutant
(A) Dot plot and median CldU tract length in indi-
cated cells after control or REV1 knockdown
(siREV1). n = 3. ****p < 0.0001, by two-tailed Mann-
Whitney test.
(B) Dot plot and median CldU tract length in indi-
cated cells after control or REV1 inhibitor treatment
(REV1i, 15 mM). REVi was added 30 min prior to la-
beling and remained throughout the experiment (n =
3). ****p < 0.0001, by two-tailed Mann-Whitney test.
(C) Proposed model for how HLTF prevents
stress-resistant DNA replication. At forks stalled
by replication stress, HLTF uses its HIRAN
domain to engage the free 30-OH group at the
stalled fork to promote fork reversal and restrain
fork progression (top). In response to transient
stalling induced by low-level replication stress,
HLTF-mediated fork remodeling facilitates tem-
plate switching and fork restart. At high levels of
replication stress, fork stalling is prolonged, and
the HLTF remodeled replication fork is suscepti-
ble to nucleolytic processing and DSB formation.
These events contribute to the sensitivity of WT
cells to replication stress. When HLTF is lost
(middle), fork progression is unrestrained and
depends on PRIMPOL-mediated repriming,
leading to discontinuous replication and S1-sen-
sitive gaps in the DNA. Mutation in HLTF’s HIRAN
domain (bottom) disrupts its ability to engage the
30-OH group at the stalled fork and prevents fork
reversal, while the HIRAN mutant protein prevents
PRIMPOL-mediated replication. Extension of the
free 30-OH group by REV1-mediated TLS sustains
unrestrained fork progression. Both PRIMPOL-dependent and REV1-dependent fork progression contribute to replication stress resistance and
potentially promote mutagenesis. Cancer cells might utilize these stress-resistant mechanisms of DNA replication to enhance tumorigenesis and che-
moresistance.
See also Figure S6.
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mechanisms by which forks progress when HLTF is disrupted.
Upon complete loss of HLTF, replication fork progression is
mediated by PRIMPOL (Figure 1E), and the S1 sensitivity of
this fork progression suggests that PRIMPOL promotes discon-
tinuous replication (Figure 1F). Importantly, disrupting HIRAN
domain binding to the 30-OH of nascent DNA also impairs fork
reversal and enables unrestrained fork progression via a distinct,
REV1-mediated process (Figures 7A and 7B). As PRIMPOL is no
longer needed for unrestrained replication (Figure 6E) in HIRAN
mutant cells, other activities of HLTF, such as its ATPase or ubiq-
uitin ligase activities, or the simple presence of HLTF on the chro-
matin, may prevent the action of PRIMPOL. In HIRAN mutant
cells, we envision that the 30 nascent DNA may be extended by
TLS polymerases recruited by REV1 (Figure 7C). Thus, the
HIRAN domain may prevent REV1-mediated DNA synthesis by
blocking the 30 end of nascent DNA and promoting fork remod-
eling. In support of this model, replication in HU-treated cells ex-
pressing the HIRAN mutant is unrestrained but insensitive to S1
nuclease activity (Figure 6D). Why then doesn’t REV1 act in the
HLTF-KOs? In yeast, Rad5 interacts with REV1 and recruits it
to replication forks under conditions of stress (Gallo et al.,
2019; Kuang et al., 2013; Pages et al., 2008). Thus, one possibil-
ity is that HLTF recruits REV1 to stalled forks, regardless of
whether the HIRAN domain binds DNA, but that TLS polymer-
ases only extend the nascent DNA strand when the 30 DNA
end is not shielded by the HIRAN domain. In WT cells, HIRAN
domain engagement could, therefore, be a regulated switch
controlling the balance between TLS and other processes that
occur at the stalled fork.
Continued DNA synthesis during S phase appears to be
important for replication stress resistance. Indeed, PRIMPOL-
or REV1-mediated DNA synthesis in the HLTF-KOs and HIRAN
mutants, respectively, drives continued replication and S phase
progression (Figures 2 and 6F). Surprisingly, in HLTF’s absence,
S phase progression is faster than in untreated WT cells, and
PRIMPOL loss does not fully suppress S phase progression (Fig-
ure 2D), suggesting that other factors may contribute to this pro-
cess. As HLTF loss reduces DNA breaks and checkpoint
signaling (Figure 3), one possibility is that a less active check-
point contributes to cell-cycle progression. In either case, effi-
cient DNA replication in HLTF’s absence could give HLTF-defi-
cient tumors a proliferative advantage.
HLTF Loss Promotes Resistance to Replication-Stress-
Inducing Agents
Our data suggest that the ability of HLTF-deficient cells to avoid
fork remodeling and to continue replication ultimately promotes
cell-cycle progression and survival under replication stress.
Moreover, when fork progression is robustly inhibited by high
HU concentrations, or when fork collapse is accelerated by addi-
tion of ATRi and HU, HLTF loss still protects cells from some of
the deleterious consequences of replication stress. Consistent
with this, DNA-damage signaling and neutral comet assays sug-
gest that HLTF loss reduces DSB formation when the replication
fork is acutely blocked (Figure 3). Moreover, survival is enhanced
upon recovery from such stress (Figure 4). This enhanced sur-
vival may be due to reducedDNA damage and fork collapse/pro-
cessing in HLTF-KO cells, avoiding cell death and/or apoptosis
upon acute replication stress.
Our studies with PRIMPOL support the idea that HLTF loss
protects cells from fork collapse and DNA break formation.
PRIMPOL loss sensitized cells to replication stress (Figure 5B),
consistent with previous reports and with its role in replication
fork restart (Kobayashi et al., 2016). Furthermore, RPA chromatin
loading, DNA-damage signaling, and DSB formation are
enhanced in PRIMPOL’s absence (Figures 5A and 5C). This sug-
gests that repriming by PRIMPOL reduces ssDNA exposure at
stalled forks and delays fork collapse. Nevertheless, HLTF loss
suppresses DSB formation in PRIMPOL-KOs and improves
cell survival. Thus, HLTF loss can protect cells in at least two
ways: first, by allowing for PRIMPOL-mediated DNA replication
and, second, by reducing replication fork collapse, independent
of PRIMPOL. We hypothesize that reduced fork collapse is due
to the inability of HLTF-deficient cells to form a reversed fork
or related structure, which, upon prolonged stress and/or fork
deprotection, is susceptible to processing (Figure 7C). In fact,
several studies implicate reversed fork processing by both exo-
nucleases and structure-specific nucleases, upon acute replica-
tion stress or specific genetic defects (Kolinjivadi et al., 2017; Le-
maçon et al., 2017; Mijic et al., 2017; Neelsen et al., 2013;
Porebski et al., 2019; Taglialatela et al., 2017). Alternatively,
HLTF might serve as a scaffold for nucleases that process the
fork into DSBs. Interestingly, HLTF loss reduced HU-induced
RPA chromatin binding, and we uncoupled this effect from
HLTF’s effects on replication catastrophe (Figure 3E). We spec-
ulate that HLTF-mediated fork remodeling allows some resec-
tion of the reversed fork that leads to RPA loading.
HIRAN mutant cells exhibit considerable replication stress
resistance (Figures 6F and 6G). This is consistent with their
continued replication using REV1-mediated TLS and with the
idea that HLTF-mediated fork remodeling could be deleterious
for cell survival upon prolonged stalling. Nevertheless, near-WT
levels of DNA-damage signaling are observed in the HIRAN mu-
tants (Figure S5D), even though thesemutants do not reverse the
fork and continue replication. One possibility is that the DNA
damage associated with the deregulated HIRAN mutant, which
retains its ubiquitin ligase and ATPase activities, results from
processing a DNA structure that is distinct from that processed
in WT cells and is less toxic for the cell. Regardless, the
enhanced replication stress resistance of HLTF-KOs and HIRAN
mutants could have significant consequences in cancer cells,
where HLTF is commonly silenced, and the resistance is consis-
tent with HLTF’s role as a tumor suppressor (Dhont et al., 2016).
These data and our studies with the ATR inhibitor (Figure 4B)
identify HLTF as a candidate biomarker for resistance to ATR in-
hibitors and other treatments increasing replication stress (Le-
cona and Fernandez-Capetillo, 2018).
The Costs and Benefits of Replication Fork Reversal
The efficiency of replication observed when HLTF is absent or the
HIRAN domain is dysfunctional raises the question of why cells
rely on fork reversal, especially if it has deleterious consequences.
We speculate that reversed forksmay act as ‘‘sensors’’ of replica-
tion stress levels. Uponmild treatments and transient fork stalling,
they may, in fact, help cells tolerate lesions and stress, providing
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time for template repair and error-free damage tolerance, via tem-
plate switching. However, by offering entry points for nucleolytic
degradation, upon prolonged fork stalling or in genetic back-
grounds that fail to protect them, such as loss of BRCA1/2 (Kolin-
jivadi et al., 2017; Mijic et al., 2017; Taglialatela et al., 2017),
reversed forks may trigger processing events that mediate che-
mosensitivity and eliminate cells dangerously prone to genome
instability. We also hypothesize that PRIMPOL or REV1 use may
allow cells to continue replication under conditions of stress, but
with the likely cost of increased mutagenesis. Indeed, PRIMPOL
is error prone (Guilliam et al., 2015a, 2015b), and HLTF loss pro-
motes mutation accumulation (Frizzell et al., 2014; Lin et al.,
2011; Seelinger and Otterlei, 2020). REV1-mediated TLS is also
mutagenic (Lawrence et al., 2000; Vaisman and Woodgate,
2017). Consistent with this, HLTF-KOs accumulate in G2 phase
after HU treatment (Figure S2A), suggesting that they undergo
some type of post-replicative repair. In fact, yeast Rad5 promotes
TLS polymerase use for mutagenic repair of undamaged DNA
templates, predominantly in G2 cells (Gallo et al., 2019). While
beneficial in yeast, this mutagenic process could be risky in
mammalian cells and may contribute to the observed association
between HLTF silencing and tumorigenesis.
Our results raise interesting questions about how cells prioritize
replication fork reversal versus error-prone TLS pathways. In
yeast, cells frequently resolve replication stress behind the fork
using template switching or TLS in G2 (Gallo et al., 2019; Wong
et al., 2020). Indeed, except for topoisomerase I inhibition (Ray
Chaudhuri et al., 2012), yeast do not utilize fork reversal to
respond to replication stress unless Rad53 is inactivated (Cotta-
Ramusino et al., 2005; Sogo et al., 2002). Our data and that of
others suggest that in mammalian cells the priorities are different,
since fork reversal is a frequently observed response (Zellweger
et al., 2015). Consistent with this idea, there are several differ-
ences in how loss of Rad5 versus HLTF affects the response to
HU. In yeast, Rad5 loss promotes sensitivity to HU, ssDNA accu-
mulation, checkpoint activation, and slowed cell-cycle progres-
sion (Gallo et al., 2019). By contrast, we show that loss of HLTF
in mammalian cells has the opposite effects. The preferred use
of fork reversal may, in fact, prioritize replication fidelity for higher
eukaryotes. It could also help eliminate cells with excessive levels
of replication stress by promoting DSB formation and cell death,
ultimately protecting the organism. Thus, loss of fork reversal
and utilization of PRIMPOL- or REV1-mediated TLS could ulti-
mately drive cancer progression and resistance.
Recent work suggests that PRIMPOL upregulation may be an
adaptive response in BRCA mutant cancer cells treated repeat-
edly with cisplatin, which allows these cells to avoid nucleolytic
fork degradation by promoting PRIMPOL-mediated replication
(Quinet et al., 2020). Similar to our work, PRIMPOL also plays a
role in replication when the remodeler SMARCAL1 is lost (Quinet
et al., 2020). However, in that case, the mechanism may be
distinct from what we observe in HLTF-KOs, as forks continue
progression in the absence of PRIMPOL when SMARCAL1 is
lost. Interestingly, PRIMPOL also promotes continued fork pro-
gression in UV-treated cells after RAD51 depletion (Vallerga
et al., 2015). These findings, taken together with our results,
imply a balance between PRIMPOL functions and fork reversal,
as recently discussed (Quinet et al., 2020). They also suggest
that the replication fork has remarkable ability to adapt in
different contexts.
HLTF Is Unique among Other Fork Remodelers
The impact of HLTF loss on cells during nucleotide depletion is
also intriguing when considered in the context of SMARCAL1
and ZRANB3, as losing each of the three proteins can rescue
phenotypes associated with fork reversal, such as the fork pro-
tection defect associated with BRCA deficiency (Kolinjivadi
et al., 2017; Mijic et al., 2017; Taglialatela et al., 2017). However,
our data suggest that there are differences in the impacts of
losing these proteins on cellular survival. SMARCAL1 or ZRANB3
loss leads to increased sensitivity to a variety of replication
stress-inducing agents and ATR inhibitors, supporting the idea
that fork reversal is beneficial (Bansbach et al., 2009; Ciccia
et al., 2009, 2012; Couch et al., 2013; Weston et al., 2012;
Yuan et al., 2012). By contrast, HLTF loss leads to increased
HU and MMC resistance and increased resistance to ATR inhib-
itors (Figure 4). While EM data suggest that all three proteins
contribute to fork reversal in vivo, these findings raise the possi-
bility that the specific products formed by each protein are
distinct and that these differences cannot be distinguished or
detected by EM. A related possibility is that these proteins might
act together. For example, if HLTF acts upstream of SMARCAL1
and ZRANB3, its loss could prevent the generation of intermedi-
ates that are more susceptible to processing than others and, ul-
timately, more detrimental to cell viability. This will need to be
tested with appropriate experiments.
Conclusion
In summary, our data suggest that HLTF is a key regulator of the
cellular replication stress response, providing an opportunity for
error-free resolution of transiently stalled forks and minimizing
continued, potentially mutagenic forms of replication. However,
an indirect consequence of this pathway choice may be detri-
mental fork processing. Although this processing could cause
cell death, it may also be viewed as a protective mechanism
that limits the proliferation of cells experiencing high levels of
replication stress. Nucleotide depletion can be induced by onco-
gene activation and deregulation of origin firing in cancer cells,
and HLTF is frequently silenced in cancer. It will, therefore, be
interesting to determine whether HLTF loss under these condi-
tions promotes survival and increased mutation, contributing to
cancer progression.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit monoclonal anti-HLTF Abcam Cat# ab183042
Mouse monoclonal anti-Chk1 Santa Cruz Biotechnology Cat# sc-8408; RRID:AB_627257
Rabbit polyclonal anti-Histone H3 Abcam Cat# ab1791; RRID:AB_302613
Mouse anti-GAPDH Abcam Cat# ab8245; RRID: AB_2107448
Rabbit monoclonal anti-phospho-Chk1 (Ser345) Cell Signaling Technology Cat# 2348; RRID:AB_331212
Rabbit monoclonal anti-phospho-Histone H2A.X (Ser139) Cell Signaling Technology Cat# 9718; RRID:AB_2118009
Rabbit polyclonal anti-phospho-Histone H3 (Ser10) Millipore Cat# 06-570; RRID:AB_310177
Rabbit polyclonal anti-phospho-RPA32 (Ser33) Bethyl Cat# A300-246A; RRID:AB_2180847
Rabbit polyclonal anti-phospho-RPA32 (Ser4/8) Bethyl Cat# A300-245A; RRID:AB_210547
Rabbit polyclonal anti-phospho-RPA32 (Thr21) Abcam Cat# ab61065; RRID:AB_946322
Mouse monoclonal anti-Replication Protein A Millipore Cat# NA19L; RRID:AB_565123
Mouse monoclonal anti-Replication Protein A Millipore Cat# MABE285; RRID:AB_11213221
Mouse monoclonal anti-PCNA Santa Cruz Biotechnology Cat# sc-56; RRID:AB_628110
Rabbit polyclonal anti-PRIMPOL Mourón et al., 2013 N/A
Mouse monoclonal anti-REV1 (sc-393022, Santa Cruz) Santa Cruz Biotechnology Cat# sc-393022
Mouse monoclonal anti-a-Tubulin Sigma-Aldrich Cat# T9026; RRID:AB_477593
Goat anti-Rabbit IgG (H+L) Secondary Antibody, HRP Thermo Fisher Scientific Cat# G-21234; RRID:AB_2536530
Anti-Mouse IgG (H+L) Polyclonal Antibody, HRP Innovative Research Cat# 81-6520; RRID:AB_87763
Goat polyclonal anti-Mouse IgG (H+L), Alexa Fluor 488 Thermo Fisher Scientific Cat# A-11001; RRID:AB_2534069
Goat polyclonal anti-Rabbit IgG (H+L), Alexa Fluor 647 Thermo Fisher Scientific Cat# A-21244; RRID:AB_2535812
Goat polyclonal anti-Rabbit IgG (H+L), Alexa Fluor 594 Thermo Fisher Scientific Cat# A-11012; RRID:AB_2534079
Goat polyclonal anti-Mouse IgG1, Alexa Fluor 568 Thermo Fisher Scientific Cat# A-21124; RRID:AB_2535766
Goat polyclonal anti-Rat IgG (H+L), Alexa Fluor 488 Thermo Fisher Scientific Cat# A-11006; RRID:AB_2534074
Goat polyclonal anti-Mouse IgG2a, Alexa Fluor 647 Thermo Fisher Scientific Cat# A-21241; RRID:AB_2535810
Mouse monoclonal anti-BrdU BD Biosciences Cat# 347580; RRID:AB_400326)
Rat monoclonal anti-BrdU Novus Biologicals Cat# NB500-169; RRID:AB_10002608
Mouse monoclonal anti-ssDNA Millipore Cat# MAB3034; RRID:AB_94645
Bacterial and Virus Strains
E.coli: DH5a New England BioLabs Cat# C2987
E.coli: NEB Stable New England BioLabs Cat# C3040
E.coli: ccdB Survival 2 Thermo Fisher Scientific Cat# A10460
Chemicals, Peptides, and Recombinant Proteins
EdU (5-ethynyl-20-deoxyuridine) Click Chemistry Tools Cat# 1149-100
DAPI (4’,6-Diamidino-2-phenylindole dihydrochloride) Sigma-Aldrich Cat# 32670
BrdU (5-Bromo-20-deoxyuridine) Sigma-Aldrich Cat# B5002
CldU (5-Chloro-20-deoxyuridine) Sigma-Aldrich Cat# C6891
IdU (5-Iodo-20-deoxyuridine) Sigma-Aldrich Cat# I7125
DMSO (Dimethyl Sulfoxide) Millipore Cat# MX1458-6
Propidium iodide (PI) Sigma-Aldrich Cat# 4170
Ampicillin sodium salt Sigma-Aldrich Cat# A0166
Chloramphenicol Sigma-Aldrich Cat# C0378
Puromycin InvivoGen Cat# ant-pr
Hydroxyurea (HU) Sigma-Aldrich Cat# H8627
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Mitomycin C (MMC) Sigma-Aldrich Cat# M4287
VE-821 Selleckchem Cat# S8007
Rev1 inhibitor (Rev1i) Sail et al., 2017 Compound #4
Alexa Fluor 488 Azide Thermo Fisher Scientific Cat# A10266
Alexa Fluor 647 Azide Thermo Fisher Scientific Cat# A10277
Trioxsalen (4,50,8-trimethylpsoralen) Sigma-Aldrich Cat# T6137
PvuII-HF New England BioLabs Cat# R3151L
RNase A Sigma-Aldrich Cat# R5503
Benzalkonium chloride Sigma-Aldrich Cat# B6295
Critical Commercial Assays
Click-iT Cell Reaction Buffer Kit Thermo Fisher Scientific Cat# C10269
NEBuilder HiFi DNA Assembly Master Mix New England BioLabs Cat# E2621
Q5 High-Fidelity DNA Polymerase New England BioLabs Cat# M0491
Monarch PCR & DNA Cleanup Kit New England BioLabs Cat# T1030
QIAquick Gel Extraction Kit QIAGEN Cat# 28706
QIAprep Spin Miniprep Kit QIAGEN Cat# 27106
QIAGEN Plasmid Midi Kit QIAGEN Cat# 12143
TransIT-LT1 Transfection Reagent Mirus Cat# MIR2300
DharmaFECT 1 Transfection Reagent Dharmacon Cat# T-2001-03
Lipofectamine 3000 Transfection Reagent Invitrogen Cat# L3000008
Lenti-X Concentrator Clontech Cat# 631231
CometAssay R&D Systems Cat# 4250-050
Experimental Models: Cell Lines
Human: U2-OS ATCC HTB-96
Human: hTERT-RPE1 ATCC CRL-4000
Human: K562 ATCC CCL-243
Human: HEK293T GenHunter Corporation Cat# Q401
Oligonucleotides
HLTF sgRNA_Fwd: CACCGTTGGACTACGCTATTACAC This paper N/A
HLTF sgRNA_Rev: AAACGTGTAATAGCGTAGTCCAAC This paper N/A
PRIMPOL sgRNA Fwd: CACCGGATAGCGCTCCAGAGACAAC Quinet et al., 2020 N/A













DC20lead: GCTTCCATCGCTGTCAAGGG This paper N/A
DC20lag: GGGAACTGTCGCTACCTTCG This paper N/A







DC50: GGGTGAACCTGCAGGTGGGCAAAGATGTCC This paper N/A
(Continued on next page)
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RESOURCE AVAILABILITY
Lead Contact
Further information and request for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Karlene
Cimprich (cimprich@stanford.edu).
Continued




DC53: GGACATCTTTGCCCACCTGCAGGTTCACCC This paper N/A
siPRIMPOL-3: GAGGAAAGCUGGACAUCGA Dharmacon J-016804-17-0002
siPRIMPOL-4: AAGAUGUUUCUGACGAAUA Dharmacon J-016804-20-0002






Plasmid: pSpCas9(BB)-2A-Puro (PX459) backbone Addgene Plasmid # 48139;
RRID:Addgene_48139
Plasmid: pX458-sgRNA-HLTF This study N/A
Plasmid: pX459-sgRNA-HLTF This study N/A
Plasmid: pX459-sgRNA-PRIMPOL This study N/A
Plasmid: pCW57.1 backbone Addgene Plasmid # 41393;
RRID:Addgene_41393
Plasmid: pCW57.1-HLTF This study N/A
Plasmid: pCW57.1-DEAA This study N/A
Plasmid: pCW57.1-R71E This study N/A
Plasmid: pCW57.1-DRING-LINKER This study N/A
Plasmid: pMD2.G Addgene Plasmid # 12259;
RRID:Addgene_12259
Plasmid: pMDLg Addgene Plasmid # 12251;
RRID:Addgene_12251
Plasmid: pRSV-Rev Addgene Plasmid # 12253;
RRID:Addgene_12253
Plasmid: pcDNA3.1(+) Invitrogen Cat# V79020
Plasmid: pcDNA3.1-Flag-HLTF Kile et al., 2015 N/A
Plasmid: pcDNA3.1-R71E Kile et al., 2015 N/A
Software and Algorithms
Fiji (ImageJ) NIH RRID:SCR_002285
OpenComet v1.3.1 www.cometbio.org
TIBCO Spotfire Perkin Elmer RRID:SCR_008858
GraphPad Prism8 Graphpad RRID:SCR_002798
MetaXpress Molecular Devices RRID:SCR_016654
Other
cOmplete, EDTA-free Protease Inhibitor Cocktail Roche Cat# 11873580001
PhosSTOP, Phosphatase Inhibitor Tablets Roche Cat# 4906845001
Greiner-Bio CELLSTAR 96 Well Cell Culture Microplate, TC
Treated, Black (8 per Pack/ 32 per Case)
Greiner Bio Cat# 655090
Fetal bovine serum for cell culture (tetracycline-free) Clontech Cat# 631367
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Materials Availability
All unique/stable reagents generated in this study are available from the Lead Contact without restriction.
Data and Code Availability
This study did not generate code. Original data have been deposited to Mendeley Data: https://doi.org/10.17632/2sg3v7zpcn.1
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture and RNA Interference
U2OS cells were maintained in DMEM (Life Technologies) supplemented with 10% FBS, 2mM L-glutamine, and 100 U/mL penicillin/
streptomycin in 5% CO2, at 37C. U2OS rescue cells were maintained in tetracycline-free FBS (Clontech) to minimize HLTF protein
expression from the doxycycline-inducible promoter. K562 cells were maintained in RPMI (Life Technologies) in suspension supple-
mented with 10% FBS, 100 U/mL penicillin/streptomycin in 5% CO2, at 37C. RPE1 cells were maintained in DMEM/F12 (Life Tech-
nologies) supplemented with 10% FBS, 100 U/mL penicillin/streptomycin and 10 mg/mL hygromycin B. siRNAs against HLTF, PRIM-
POL (CCDC111) and REV1 (smart pool) were purchased from Dharmacon and transfected using Dharmafect 1 (Thermo Fisher
Scientific) according to the manufacturer’s directions.
CRISPR/Cas9-mediated Knockouts
The single-guide RNAs (sgRNA) used to knockout HLTF or PRIMPOL have been previously described (Kile et al., 2015; Quinet et al.,
2020). sgRNAs were cloned into the pX458 and pX459 plasmid (Ran et al., 2013)(Addgene). RPE1 cells were transfected with the
pX458-sgRNA-HLTF. U2OS cells were transfected with pX459-sgRNA-PRIMPOL or pX459-sgRNA-HLTF plasmids, and K562 cells
were transfected with pX459-sgRNA-HLTF. To generate U2OS HLTF-PRIMPOL dKO cells, we transfectedWT and HLTF-KO#3 cells
with pX459-sgRNA-PRIMPOL. For RPE1 cells, single GFP positive cells were sorted into a 96-well plate 48h post-transfection. For
K562 cells, 24h post-transfection, cells were selected with 1 mg/mL puromycin for 48h to enrich for positive transfectants then pro-
pidium iodide (PI) staining was performed and single PI-negative cells were sorted into a 96-well plate. For U2OS cells, 300 cells
were plated in 150mm dishes. For all cell types, cells were allowed to form colonies in the incubator. For RPE1 and K562 cells, well-
isolated single colonies were further expanded and screened by western blot analysis for the loss of HLTF expression. For U2OS
cells, single colonies were isolated using cloning rings and further expanded to screen for loss of HLTF and/or PRIMPOL expression
by western blot. All knockout clones were verified by sequencing (see Table S1).
Generation of HLTF-rescue cell lines
FLAG-tagged WT and HIRAN mutant HLTF (R71E) were cloned from pcDNA3.1(+) backbone (Kile et al., 2015) into pCW57.1 using
NEB HiFi assembly. Cloned fragments were sequenced verified. pCW57.1-HLTF vectors were packaged into lentivirus particles us-
ing the 3rd generation lentiviral packaging system (pMD2.G, pMDLg & pRSV-Rev) in HEK293T cells, with TransIT-LT1 Transfection
Reagent (Mirus). Virus-containing media was harvested 48 & 72h post-transfection and filtered through 0.45 mm PES membrane sy-
ringe filter to eliminate packaging cells. Lentivirus particles were further concentrated using Lenti-X Concentrator (Clontech) accord-
ing to the manufacturer’s instructions. U2OS HLTF-KO3 cells were infected with the purified lentivirus particles with the presence of
Polybrene (1 mg/mL, Millipore) overnight. 48h post-infection, 1 mg/mL Puromycin was added to the media to start the selection of
infected cells. The resistant cells were clonally isolated using cloning cylinders and maintained in Tetracycline-free FBS with 1 mg/
mL Puromycin throughout.
Drugs and Cell Culture Supplements
HU (Sigma-Aldrich), MMC (Sigma-Aldrich) or ATR inhibitor (VE821, Selleckchem) were applied as indicated. dNTP analogs BrdU,
CldU, IdU (Sigma-Aldrich), and EdU (Life Technologies) were used as indicated. REV1 inhibitor (REV1i) was previously described
(compound 4 in (Sail et al., 2017)) and used as indicated.
METHOD DETAILS
DNA Spreading
U2OS, K562, RPE1 and derived cell lines were used to monitor DNA replication tracts essentially as described (Jackson and Pombo,
1998). IdU / CldU pulse labeling is 20min each in Figures 1C–1F and 30min each in Figures 6D, 6E, 7A, and 7B, or as stated in sup-
plementary figures legends. For S1 nuclease experiments, cells were trypsinized and collected after labeling, split into two samples,
permeabilized and either mock-treated (open circle) or S1-nuclease treated (closed circle, 20U/mL). DNA spreading was then per-
formed and replication tracts were visualized using a Zeiss OBSERVER.Z1 INVERTED microscope and a Plan-APO 40x/1.4 Oil DIC
(UV) VIS-IR objective. Fluorescent images were acquired using an Axiocam 506 mono camera (conversion = 0.1135) connected to
the microscope. ssDNA was also stained to make sure that DNA tracts are not broken. Tracts that represent replication fork termi-
nation events (red-green-red or red only tracts) or new origin firing during the CldU labeling (green only) are excluded from the anal-
ysis. In all experiments, CldU tract lengths were measured only when preceded by IdU labeling to quantify ongoing replication forks
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(green followed by red staining pattern). For quantification, at least 2 slides per sample were prepared for each experimental repeat.
To avoid bias, after immunodetection, each pair of slides was blinded and we randomly selected 10 fields of view from each slide and
acquired images. Hence, for each experiment, we acquired 20 images for each sample. DNA fiber length was measured using an
ImageJ plug-in. We randomly score similar number of fibers (15) from each image. At least 200 replication tracts per sample
were measured for each replicate.
Immunofluorescent (IF) staining
For RPA chromatin binding experiments, cells were pre-extracted with CSK100 (100mMNaCl, 300mM sucrose, 3mMMgCl2, 10mM
MOPS & 0.5% Triton X-100) buffer at 4C for 5 min before fixation. Otherwise, cells were immediately fixed with 4% PFA/PBS for
20 min, permeabilized with 0.5% Triton X-100 for 5 min, blocked in 1% BSA/PBS for 20 min at RT. For EdU staining, the Click-iT
reaction was carried out following permeabilization using the Click-iT Cell Reaction Buffer kit (Thermo Fisher C10269) and Alexa Fluor
488 Azide (Thermo Fisher A10266) according to the manufacturer’s guidelines. For BrdU staining, DNA was denatured with 2 N HCl
for 30 min and neutralized for 10 min with PBS prior to the blocking step. The primary antibodies were diluted in 1% BSA/PBS and
incubated overnight at 4C: mouse anti-RPA34 (Millipore NA19L, 1:500), mouse anti-RPA34 (Millipore MABE285, 1:500), rabbit anti-
phospho-Histone H2A.X (ser139) (Cell Signaling Technology 9718, 1:500), rabbit anti-phospho-RPA32 (Thr21) (Abcam ab61065,
1:500), rabbit anti-phospho-RPA32 (Ser4/8) (Bethyl Laboratories A300-245A), mouse anti-BrdU (BD Biosciences clone B44,
1:100), rabbit anti-phospho-H3 (Ser10) (Millipore 06-570, 1:400). Cells were washed 3x with PBS. Secondary antibodies (diluted
1:1000) and DAPI (5 mg/mL) were diluted in 1%BSA and incubated for 1 h at RT. Cells were washed 3xwith PBS and then submerged
in PBS during image acquisition.
Quantitative Image-Based Cytometry (QIBC)
Images were acquired in an unbiased fashion with the Molecular Devices ImageXpress Micro automated inverted epifluorescence
microscope. Acquisition times for different channels were adjusted to obtain images in non-saturating conditions for all the treat-
ments analyzed. After acquisition, the imageswere analyzedwith automatedMetaXpress image analysis software. At least 3000 cells
were analyzed per condition, and each experiment was repeated at least 3 times. DAPI signal was used for generating a mask that
identified each individual nucleus as an individual object. This maskwas then applied to quantify pixel intensities in the different chan-
nels for each individual cell/object. After quantification, the quantified values for each cell (mean and total intensities, area, perimeter)
were extracted and exported to the proprietary Spotfire software. Spotfire was used to visualize key features of replication stress and
DNA damage signaling for thousands of cells and quantify percentages and average values in cell populations. Spotfire filtered data
was then used to generate plots using Prism8 (GraphPad Prism version 8.0.2 (159) for Mac OS X, GraphPad Software, La Jolla Cal-
ifornia USA, https://www.graphpad.com) software.
S to G2 cell cycle progression assay
Asynchronously grown U2OS cells were pulse labeled with EdU (10 mM) for 20min, then washed with warm PBS and chased with or
without HU (50 mM) for different times, up to 8h. At the end of the chase, cells were pulse labeled again with (50 mM) BrdU for another
20min. Cells are then fixed with 4% PFA before immunofluorescent staining to detect EdU and BrdU incorporation. DNA content is
determined by DAPI counterstaining. QIBC was used to acquire fluorescent images and determine Mean EdU, BrdU fluorescent in-
tensities and total DAPI intensity at the single cell level. Cells stain positive or negative for either or both nucleotide labeling were
further determined. To determine the percentage (%) of EdU+, BrdU- cells corresponding to cells that progressed from S to G2 during
the chase time, number of EdU+, BrdU- cells with G2/4N DNA content were combined with EdU+, BrdU- cells with G1/2N DNA con-
tent divided by 2 (1 G2 cell gives rise to 2 G1 cells), then normalized to the total cell number.
Neutral comet assay
U2OS or K562 cells were mock treated or treated with 3mM HU for 24h to induce DSB formation before harvest. For U2OS cells,
trypsin was applied to obtain a single cell suspension. For K562 cells, cells were directly harvested from suspension culture. Cells
were then processed using Trevigen’s CometAssay kit (Cat# 4250-050) following the manufacturer’s instructions. Electrophoresis
was performed at 1V/cm for 45min at 4C. SYBR-Gold stained single cells were visualized using a Zeiss OBSERVER.Z1 INVERTED
microscope and a Plan-APO 40x/1.4 Oil DIC (UV) VIS-IR objective. Fluorescent images were acquired using an Axiocam 506 mono
camera (conversion = 0.1135) connected to the microscope. For each experimental repeat, at least 60 individual cells were imaged
per sample. Comet tail moment was determined using OpenComet v1.3.1 (www.cometbio.org) as an ImageJ plugin.
Clonogenic survival assay
U2OS cells weremock treated or treatedwith drug as indicated in the figure legends. For HU andMMC treatment, treatment timewas
24h. For HU+ATRi treatment, increased treatment time was applied to the cells. After drug treatment, cells were washed twice with
warm PBS and released into fresh growth medium for 10–14 days to allow for colony formation. Colonies were visualized by crystal
violet staining and counted. Percentage of survival (% survival) is calculated by normalizing the number of colonies from treated sam-
ples to mock treated samples.
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Western blot
Equal number of cells were collected for each sample and lysed in Laemmli sample buffer supplemented with protease inhibitor
cocktail (Sigma) and beta-mercaptoethanol (5%) by heating at 95C for 5 min. Proteins were separated by SDS-PAGE, and trans-
ferred to a PVDF membrane (Millipore). Primary antibodies were: rabbit anti-HLTF (Abcam ab183042), mouse anti-alpha-tubulin
(Sigma T9026), rabbit anti-phospho-Chk1 (Ser345) (Cell Signaling Technology 2348), mouse anti-Chk1 (sc-8408, G4, Santa Cruz),
rabbit anti-phospho-RPA32 (Ser33) (Bethyl Laboratories A300-246A), rabbit anti-phospho-RPA32 (Ser4/8) (Bethyl Laboratories
A300-245A), rabbit anti-phospho-Histone H2A.X (ser139) (Cell Signaling Technology 9718), mouse anti-RPA34 (Millipore NA19L),
mouse anti-PCNA (sc-56, Santa Cruz), rabbit anti-PRIMPOL (Mourón et al., 2013), rabbit anti-Histone H3 (Abcam ab1791), mouse
anti-REV1 (sc-393022, Santa Cruz), andmouse anti-GAPDH (Abcam ab8245). Secondary antibodies were goat anti-rabbit HRP (Mo-
lecular Probes G21234) and goat anti-mouse HRP (Invitrogen 81-6520). Chemi-luminescence was carried out using the Immobilon
HRP substrate (Millipore WBKLS0500), and blots were imaged with a FluorChem HD2 from Alpha Innotech.
Protein purification
Human HLTF was expressed in Sf-9 insect cells and purified as described (Chavez et al., 2018). UBA1 (Soss et al., 2011), ubiquitin
(Brzovic et al., 2006), RFC (Yao et al., 2003), RAD6/RAD18 (Masuda et al., 2010) and UBC13/MMS2 (Campbell et al., 2012), which
were expressed and purified as previously described, were kindly provided by Brian Kelch (University of Massachusetts Medical
School, yeast RFC), Yuji Masuda (Nagoya University, Japan, human Rad6/Rad18), Mark Glover (University of Alberta, human
Ubc13/Mms2) and John Pascal (University of Montreal, human PCNA.
ATPase assays
ATPase reactions were carried out in ATPase buffer (40mMTris pH 7.76, 50mMNaCl, 5 mMMgCl2, and 1mMTCEP). Wild-type and
the R71E mutant were assayed at 25 nM in the presence of the indicated amount of fork DNA (annealed oligos DC40, DC20:40,
DC20lead, DC20lag) and 1 mM g32P-ATP. Reactions were incubated at 37C for 30 min and quenched with EDTA. 1mL was spotted
onto a TLC PEI cellulose F chromatography plate (Millipore Sigma) and free phosphate separated from non-hydrolyzed ATP using a
mobile phase of 1 M formic acid and 0.25 M LiCl. Results were visualized using autoradiography and quantified with GelAnalyzer.
Fork regression assay
Fork regression was performed as previously described (Chavez et al., 2018). Briefly, 50-32P-labeled DC48 and DC50 were annealed
in 1X SSC buffer (15 mM sodium citrate pH 7, 150 mM NaCl), DC52 and DC53 were annealed in a separate reaction. Forked sub-
strates were formed by mixing the annealed DC48/DC50 in a 1:1.5 ratio with annealed DC52/DC53. Reactions were carried out at
37C in ATPase buffer containing 10 nM HLTF, 2 mM ATP, 0.1 mg/mL BSA, and 1 nM of forked substrate. Reactions were stopped
at each time point through the addition of one unit of Proteinase K (Sigma) to 10 mL of sample. The samples were resolved by native
PAGE and visualized by autoradiography. Quantification was carried out with GelAnalyzer.
Ubiquitin ligase assays
DNA oligonucleotides DC31 and DC75 were annealed in X SSC buffer (15 mM sodium citrate pH 7, 150 mM NaCl) to produce a
duplex with a 50-ssDNA overhang. Reactions were carried out in ubiquitylation buffer (40 mM Tris pH 7.76, 50 mM NaCl, 8 mM
MgCl2, 10% glycerol, 0.5 mM ATP, and 0.1 mg/mL BSA. Unless otherwise noted, each reaction contained 0.1 mM Uba1, 0.01 mM
yRFC, 0.2 mM Rad6/Rad18, 0.2 mM Ubc13/Mms2, 0.05 mM annealed DC 31/DC75, 50 mM ubiquitin, 0.1 mM PCNA, and 0.2 mM
HLTF. Reactions were incubated at 30C for 60 min and stopped by the addition of 2X Laemmli buffer. Samples were analyzed
by western blot using an anti-PCNA antibody (PC10, Invitrogen).
EM analysis of DNA replication intermediates (RIs) in human cells
EM analysis of DNA replication intermediates (RIs) was performed as previously described (Zellweger and Lopes, 2018). Briefly,
asynchronous cells were treated with 50 mM HU for 1h and harvested. In vivo crosslinking was performed twice by addition of
4,50,8-trimethylpsoralen (Sigma T6137) to a final concentration of 10 mg/mL and UV irradiation at 365nm for 3min (UV Stratalinker
1800; Agilent Technologies). Cells were then lysed with lysis buffer (1.28 M sucrose, 40 mM Tris-Cl, pH 7.5, 20 mM MgCl2, and
4% Triton X-100) for 10min on ice. Nuclei were collected by centrifugation and washed. Digestion was performed with digestion
buffer (800 mM guanidine-HCl, 30 mM Tris-HCl, pH 8.0, 30 mM EDTA, pH 8.0, 5% Tween 20, 0.5% Triton X-100, and 1mg/ml pro-
teinase K) at 50C for 2h. Genomic DNA was extracted from these cell lysates by chloroform: isoamylalcohol phase separation and
isopropanol precipitation. The extracted genomic DNAwas washed and briefly air-dried before resuspension in TE (Tris-EDTA) over-
night. The obtained genomic DNA was digested with PvuII-HF (NEB, R3151L) and Rnase A (Sigma-Aldrich, R5503). The digested
DNA was concentrated used for electron microscopy analysis. The digested DNA was mixed with benzyldimethylalkylammonium
chloride (BAC, Sigma Aldrich B6295), spread on a water surface and loaded onto carbon-coated 400-mesh magnetic nickel grids.
The DNA-loaded grids were coated with 13nm of platinum by platinum-carbon rotary shadowing (Leica BAF060) and analyzed using
a transmission electron microscope (Tecnai G2 Spirit; FEI; LaB6 filament; high tension % 120 kV). Images were taken at different
magnifications using a side mount charge-coupled device camera (2,600 3 4,000 pixels; Orius 1000; Gatan, Inc.). The images
were processed with DigitalMicrograph Version 1.83.842 (Gatan, Inc.) and analyzed using ImageJ.
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QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using Prism8 (GraphPad Software). Details of how data is presented, including the definition of
center (mean or median) and error bars can be found in the figure legends. Details of statistical test for each experiment, including
the type of statistical tests used and the number of repeats, can be found in the figure legends. Statistical test results, presented as
levels of significance, are shown in the figures. In all cases: ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Statistical differences in DNA fiber tract lengths were determined byMann-Whitney test when two samples were compared. When
multiple groupswere compared, Kruskal-Wallis test was used. Statistical differences for all other grouped analyses, i.e., frequency of
fork reversal (EM), cell survival, chromatin-bound RPA and gH2AX intensities in RPA positive cells (QIBC), percentage of cells positive
for chromatin-bound pRPA (QIBC) were assessed by one-way ANOVA followed by Dunnett’s test using WT U2OS cells as control.
Statistical differences in percentage of cells positive for EdU, negative for BrdU (QIBC) in the S to G2 progression assay were deter-
mined by two-way ANOVA followed by Dunnett’s test using WT U2OS cells as control.
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Supplemental Table 1. Sequencing confirmation of HLTF-KO, PRIMPOL-KO and 
HLTF-PRIMPOL-double KO CRISPR clones. Related to Figure 1. 
 
HLTF-KO clones: 
K562     -GTCATGTGGTTGGACTACGCTATTACACGGGAGTAGTTA- 
KO4_v1   -GTCATGTGGTTGGACTACGCTATT-CACGGGAGTAGTTA- 
KO4_v2   -GTCATGTGGTTGGACTACGCTATTAC--GGGAGTAGTTA- 
KO5_v1   -GTCATGTGGTTGGACTAC--------ACGGGAGTAGTTA- 
KO5_v2   -GTCATGTGGTTGGACTACGCTATTA---GGGAGTAGTTA- 
KO5_v3   -GTCATGTGGTTGGAC-----------ACGGGAGTAGTTA- 
 
RPE1     -GTCATGTGGTTGGACTACGCTATTACACGGGAGTAGTTA- 
KO28     -GTCATGTGGTTGGACTACGCTATTA-ACGGGAGTAGTTA- 
KO50_v1  -GTCATGTGGTTGGACTACGCTATT-CACGGGAGTAGTTA- 




U2OS     -AAGATGATGATAGCGCTCCAGAGACAACAGGCCATGGAT- 
KO6_v1   -AAGATGATGATAGCGCTCCAGAG---ACAGGCCATGGAT- 
KO6_v2   -AAGATGATGATAGCGCTCCAGAG---ACAGGCCATGGAT- 
KO8_v1   -AAGATGATGATAGCGCTCCAGAGA---CAGGCCATGGAT- 
KO8_v2   -AAGATGATGATAGCGCTCCAGA----ACAGGCCATGGAT- 
KO9_v1   -AAGATGATGATAGCGCTCCAGAGA--ACAGGCCATGGAT- 
KO9_v2   -AAGATGATGATAGCGCTCCAGAGA----AGGCCATGGAT- 




U2OS     -AAGATGATGATAGCGCTCCAGAGACAACAGGCCATGGAT- 
dKO1_v1  -AAGATGATGATAGCGCTCCAGA-----CAGGCCATGGAT- 
dKO1_v2  -AAGATGATGATAGCGCTC-------AACAGGCCATGGAT- 
dKO3_v1  -AAGATGATGATAGCGCTCCAGAGA--ACAGGCCATGGAT- 
dKO3_v2  -AAGATGATGATAGCGCTCCAGA----ACAGGCCATGGAT- 
dKO3_v3  -AAGATGATGATAGCGCTCCAGAG--AACAGGCCATGGAT- 
dKO5_v1  -AAGATGATGATAGCGCTCCAGAGAC-ACAGGCCATGGAT- 
dKO5_v2  -AAGATGATGATAGCGCTCCAGAG-----AGGCCATGGAT- 
dKO7_v1  -AAGATGATGATAGCGCTCCAGAGA--ACAGGCCATGGAT- 
dKO7_v2  -AAGATGATGATAGCGCTCCAG----AACAGGCCATGGAT- 
 
 
Genomic DNA from HLTF-KO, PRIMPOL-KO and HLTF-PRIMPOL-double KO clones used in 
this study was isolated and used to subclone the genomic region containing the CRISPR-
targeting sites into a plasmid and then analyzed by Sanger-sequencing. Clones with multiple 
edited variants are also presented. Genomic sequences corresponding to the gRNA are in blue; 
PAM sequences are in green. Dashed lines representing deletions and insertions are in red.    
 
Supplemental Figure 1. Effects of HLTF loss on unrestrained replication fork progression. 
Related to Figure 1.   
(A) Expression of HLTF in U2OS, K562 and RPE1 HLTF-KO cell lines generated by CRISPR-
targeting. Whole cell lysates were separated by SDS-PAGE and then immunoblotted to detect 
the indicated proteins. 
(B) Dot plot showing CldU tract length in K562 (left) and RPE1 (right) HLTF-KO cell lines. Cells 
were labeled with IdU then CldU for 20 min each in K562 cells, and 30min each in RPE1 cells. 
Cells were also either mock treated (open circle) or treated with 50 μM HU (closed circle) during 
CldU labeling. Results from three independent experiments were pooled and shown. Green line 
represents median. ns, not significant; ****, p < 0.0001, by two-tailed nonparametric Mann-
Whitney test. 
(C) Left, schematic of S1 nuclease cleavage of labeled DNA fiber containing ssDNA gap. Right, 
dot plot showing CldU tract length at ongoing replication forks in WT and HLTF-KO U2OS cells. 
Cell labeling and HU treatment were performed as described in Figure 1C. After labeling, cells 
were collected, split into two samples, permeabilized and either mock-treated (open circle) or S1 
nuclease treated (closed circle, 20U/mL). DNA spreading was then performed. Results from two 
independent experiments were pooled and shown. Green line represents median. ns, not 
significant; ****, p < 0.0001, by two-tailed nonparametric Mann-Whitney test.  
(D) Confirmation of PRIMPOL knockdown by siRNA in WT and HLTF-KO U2OS cells. Whole cell 
lysates were separated by SDS-PAGE and then immunoblotted to detect the indicated proteins.  
(E) Dot plot of CldU tract lengths after control or PRIMPOL (siPRIMPOL-4) knockdown in WT or 
HLTF-KO2 U2OS cells. Cells were labeled and treated as described in Fig. 1E. Results from two 
independent experiments were pooled and shown. Green line represents median. ns, not 
significant; ****, p < 0.0001, by two-tailed nonparametric Mann-Whitney test. 
(F) Western blot showing PRIMPOL levels in HLTF-KO cells versus WT U2OS cells treated with 
50 μM HU for 20 min. Total protein extracts from cell lysates were separated by SDS-PAGE and 
then immunoblotted to detect the indicated proteins. 
(G) Confirmation of PRIMPOL knockout in WT and HLTF-KO U2OS cells by CRISPR-targeting. 
Whole cell lysates were separated by SDS-PAGE and then immunoblotted to detect the indicated 
proteins.  
(H) Dot plot of CldU tract length in HLTF-KO cells and HLTF-PRIMPOL-double KOs (dKOs) cells. 
Cells were labeled with IdU then CldU for 30 min each, and either mock-treated or treated with 
50 μM HU during CldU labeling. Results from three independent experiments were pooled and 
shown. Green line represents median.  For HU treated samples, each mutant clone is compared 
to WT cells. ns, not significant; ****, p < 0.0001, by two-tailed nonparametric Mann-Whitney test.   
 
  
Supplemental Figure 2. Effects of HLTF loss on cell cycle progression in various cell lines. 
Related to Figure 2. 
(A) Left, cell cycle distribution of WT and HLTF-KO U2OS cells. Cells were either HU (50 μM) or 
mock-treated for the indicated times before BrdU labeling for 20min, then fixed and stained for 
DAPI, BrdU and phospho-H3 Ser10 (pH3). Cell cycle phases were defined as follows: G1 cells 
were BrdU-negative with G1/2n DNA content; S phase cells were BrdU positive; G2 cells were 
BrdU negative, pH3 negative with G2/4n DNA content; M phase cells were BrdU negative, pH3 
positive with G2/4n DNA content. Results shown are mean ± SEM of two independent 
experiments. Right, quantification of cell cycle distribution corresponding to 6h time point shown 
on the left. ns, not significant; *, p<0.05; **, p<0.01, by two-tailed t-test.  
(B) QIBC plots of total DAPI intensity versus mean EdU intensity in untreated WT and HLTF-KO2 
U2OS cells. EdU+ and BrdU- cells are shown in red. 1500 cells were randomly selected for each 
sample to generate the scatter plot.  
(C) S-G2 progression assay was carried out on WT and HLTF-KO RPE1 cells. Experiments were 
carried out as described in Figure 2A. Results shown are mean ± SEM of three independent 
experiments. Statistics: HU treated samples were compared. ****, p<0.0001, by two-way ANOVA 
followed by Dunnett’s test. Test results of HLTF-KO clones vs. WT were shown. 
(D) S-G2 progression assay as described in Figure 2A in untreated WT, HLTF-KOs, PRIMPOL-
KOs or HLTF-PRIMPOL-double KOs (dKOs).  Results shown are mean ± SEM of three 
independent experiments. Statistics: ns, not significant; *, p<0.05, by two-way ANOVA followed 
by Dunnett’s test. Test results of mutant clones vs. U2OS were shown. 
(E) S-G2 progression assay was carried out on WT and HLTF-KO U2OS cells following control 
or PRIMPOL knockdown (siPRIMPOL-3). Experiments were carried out as described in Figure 
2A either in the absence (left) or presence (right) of 50 μM HU between EdU and BrdU labeling. 
Results shown are mean ± SEM of three independent experiments. Statistics: **, p<0.01; ***, 
p<0.001; ****, p<0.0001, by two-way ANOVA followed by Dunnett’s test. Test results of HLTF-
KOs, siPRIMPOL vs. U2OS, siPRIMPOL were shown. 
  
Supplemental Figure 3. HLTF loss limits DNA damage signaling, RPA chromatin binding 
and DSB formation. Related to Figure 3.   
(A) WT or HLTF-KO K562 cells were treated with 3 mM HU for 24h before being collected for 
neutral comet assay. At least 200 individual cells were scored for tail moment in each independent 
experiment. Results from 2 independent experiments were pooled and shown as a whisker plot. 
****, p < 0.0001, by two-tailed nonparametric Mann-Whitney test. 
(B) WT and HLTF-KO U2OS cells were treated for the indicated times with 3 mM HU and 5 μM 
ATRi. Total RPA, γH2AX intensities and percentage (%) of pRPA T21 or S4/8 positive cells were 
measured as described in Fig. 3C. Results shown are mean ± SEM of three independent 
experiments. Each HLTF-KO clone is compared to WT cells in a statistical test.  ns, not significant; 




Supplemental Figure 4. HLTF loss protects cells from replication stress in a PRIMPOL-
independent manner. Related to Figure 5.  
(A) WT and HLTF-KO (clone #3) U2OS cells were treated for the indicated times with 3 mM HU 
after control or PRIMPOL (siPRIMPOL-3) knockdown. Total RPA and γH2AX intensities were 
measured as described in Figure 3C. Results shown are mean ± SEM of three independent 
experiments. ns, not significant; *, p>0.05 by one-way ANOVA followed by Dunnett’s test. Test 
results between U2OS-siGL3 vs other samples were shown.  
(B) Survival assay in U2OS cells after control or PRIMPOL (siPRIMPOL-3) knockdown in WT or 
HLTF-KO (clone #3) U2OS cells. Cells were mock-treated or treated with increasing 
concentrations of HU for 24h before release into fresh growth medium for 10 -14 days for survival 
analysis. Results shown are mean ± SEM of three independent experiments. WT and HLTF-KO 
cells after siPRIMPOL were compared in a statistical test. ns, not significant; *, p<0.05; **, p<0.01 
by two-tailed t-test.    
Supplemental Figure 5. The HLTF HIRAN mutant promotes an alternative mechanism of 
stress-resistant DNA replication. Related to Figure 6. 
(A) Western blot confirming WT or R71E HLTF expression in HLTF-KO (clone #3) cells with or 
without 200ng/ml of doxycycline induction for 2h. Total protein extracts from cell lysates were 
separated by SDS-PAGE and then immunoblotted to detect the indicated proteins. 
(B) Dot plot showing CldU tract length in WT or HLTF-KO U2OS cells, or in HLTF-KO U2OS cells 
expressing WT-HLTF (2 clones) or R71E-HLTF (2 clones). Cells were labeled with IdU then CldU 
for 30 min each, and either mock-treated or treated with 50 μM HU during CldU labeling. Results 
from three independent experiments were pooled and shown. Green line represents median. ****, 
p<0.0001. HU treated samples are compared using Kruskal-Wallis test, followed by Dunn’s test.  
(C) S-G2 progression assay described in Figure 2A showing % of EdU+, BrdU- U2OS WT, HLTF-
KO (clone #3), or HLTF-KO (clone #3) cells expressing WT-HLTF (2 clones) or R71E-HLTF (2 
clones) without HU treatment. Results shown are mean ± SEM of three independent experiments. 
(D) WT, HLTF-KO (clone #3), or HLTF-KO (clone #3) U2OS cells expressing WT-HLTF (2 clones) 
or R71E-HLTF (2 clones) were treated with 3mM HU for 6h. Total γH2AX intensities and the % of 
pRPA-T21 positive cells were measured in RPA-positive cells as described in Figure 3C. Results 
shown are mean ± SEM of three independent experiments. WT U2OS cells and HLTF-KO cells 
expressing WT-HLTF or R71E-HLTF are compared in a statistical test. ns, not significant, by one-




Supplemental Figure 6. Confirmation of REV1 knockdown. Related to Figure 7. 
(A) Western blot confirming REV1 knockdown by siRNA in WT, HLTF-KO (clone #3) U2OS cells, 
and in HLTF-KO (clone #3) U2OS cells expressing WT-HLTF (2 clones) or R71E-HLTF (2 clones). 
Total protein extracts from cell lysates were separated by SDS-PAGE and then immunoblotted to 
detect the indicated proteins. 
